The World Congress for Clinical Trials in Diabetes will bring together over 300 representatives from regulatory agencies and the pharmaceutical industry across a range of disciplines including endocrinologists, cardiologists, neurologists and nephrologists.
MELBOURNE, Australia, 27 November 2017: Dimerix Limited (ASX: DXB), a clinical stage biotechnology company announces that Associate Professor Dr David Packham has been invited to present both an oral and poster presentation at the 2nd World Congress for Clinical Trials in Diabetes between November 27-28 in Berlin, Germany.
The World Congress for Clinical Trials in Diabetes will bring together over 300 representatives from regulatory agencies and the pharmaceutical industry across a range of disciplines including endocrinologists, cardiologists, neurologists and nephrologists. The representatives are thought leaders in clinical trials for treatments for complications of diabetes, including kidney disease.
This presentation follows the release of detailed subgroup analysis that was presented at the American Society of Nephrology (ASN) in New Orleans on November 2, which highlighted compelling efficacy signals in diabetic nephropathy patients. In the presentations this week, Associate Professor Dr Packham will be discussing the details of the mechanism of action of DMX-200 in this significant patient group, and also a detailed safety analysis of this group.
The abstract describing the results was initially selected for a poster presentation and subsequently deemed to be one of the most significant among the poster presentations and therefore also selected for oral presentation.
According to the 2017 US Center for Disease Control (CDC) Chronic Kidney Disease Fact Sheet, around 44% of new diagnosis of Chronic Kidney Disease in the USA is due to diabetes. Estimates of the prevalence of Chronic Kidney Disease in the US from all causes vary form 10-15% of the adult population, making diabetic nephropathy a major and growing health problem.
Associate Professor Dr David Packham, Director of the Melbourne Renal Research Group said, “Preliminary efficacy data from the DMX-200 Phase 2a study suggests that clinically and statistically significant effects on proteinuria were observed in patients with diabetic nephropathy, which we believe may translate to improved renal functional outcomes.”
Kathy Harrison, Dimerix CEO said: “These types of conferences are key to showcasing the DMX-200 program on the world stage and are important for its commercialisation. We are grateful to have been given both a poster and oral presentation to promote the impact that DMX-200 had on patients in our phase 2a trial.”
The poster will be available for viewing from 9:00 am on Monday 27th November.
Details of the oral presentation
Session date / time: Monday 27 November from 4:30 pm
Session title and details: A Phase 2a Trial of DMX-200: Synergistic Blockade of AT1R and CCR2 in a Subgroup of Patients with Diabetic Nephropathy
